Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 6:01 pm Sale | 13G | Jasper Therapeutics Inc. JSPR | Avidity Partners Management LP | 0 0.000% | -760,000 (Position Closed) | View |
| 2024-11-14 3:32 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | Soleus Private Equity Fund III L.P. | 1,343,665 9.000% | 1,343,665 (New Position) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Jasper Therapeutics Inc. JSPR | BlackRock Inc. BLK | 800,028 5.300% | 0 (Unchanged) | View |
| 2024-11-04 12:05 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 189,270 1.250% | 189,270 (New Position) | View |
| 2024-10-22 6:06 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | BlackRock Inc. BLK | 800,028 5.300% | 800,028 (New Position) | View |
| 2024-03-27 4:26 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | Avidity Partners Management LP | 760,000 5.100% | 760,000 (New Position) | View |
| 2024-02-14 6:18 pm Sale | 13G | Jasper Therapeutics Inc. JSPR | CITADEL ADVISORS LLC | 230,620 0.200% | -3,498,450 (-93.82%) | View |
| 2024-02-14 4:18 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | Qiming U.S. Healthcare Fund II L.P. | 928,964 6.200% | 928,964 (New Position) | View |
| 2024-02-14 09:41 am Sale | 13G | Jasper Therapeutics Inc. JSPR | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -9,900,000 (Position Closed) | View |
| 2024-02-12 6:00 pm Sale | 13D | Jasper Therapeutics Inc. JSPR | Carlyle Group Inc. CG | 1,066,189 7.100% | -7,695,702 (-87.83%) | View |
| 2024-02-09 8:36 pm Purchase | 13D | Jasper Therapeutics Inc. JSPR | Velan Capital Investment Management LP | 1,471,903 9.800% | 1,471,903 (New Position) | View |
| 2024-02-05 09:15 am Purchase | 13G | Jasper Therapeutics Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 7,130,625 6.390% | 1,443,491 (+25.38%) | View |
| 2024-02-02 09:50 am Purchase | 13G | Jasper Therapeutics Inc. JSPR | Soleus Capital Master Fund L.P. | 987,096 8.800% | 987,096 (New Position) | View |
| 2023-10-10 11:15 am Purchase | 13G | Jasper Therapeutics Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 5,687,134 5.130% | 5,687,134 (New Position) | View |
| 2023-02-27 4:05 pm Unchanged | 13D | Jasper Therapeutics Inc. JSPR | Velan Capital Investment Management LP | 11,219,036 10.200% | 0 (Unchanged) | View |
| 2023-02-14 08:26 am Purchase | 13G | Jasper Therapeutics Inc. JSPR | CITADEL ADVISORS LLC | 3,729,070 9.900% | 47,868 (+1.30%) | View |
| 2023-02-13 4:49 pm Unchanged | 13G | Jasper Therapeutics Inc. JSPR | ROCHE FINANCE LTD | 4,624,606 4.200% | 0 (Unchanged) | View |
| 2023-02-10 4:18 pm Sale | 13G | Jasper Therapeutics Inc. JSPR | AMGEN INC AMGN | 1,009,929 0.900% | -1,690,071 (-62.60%) | View |
| 2023-02-06 4:43 pm Purchase | 13G | Jasper Therapeutics Inc. JSPR | BIOTECHNOLOGY VALUE FUND L P | 9,900,000 9.100% | 9,900,000 (New Position) | View |
| 2023-01-31 4:15 pm Purchase | 13D | Jasper Therapeutics Inc. JSPR | Carlyle Group Inc. CG | 8,761,891 8.000% | 3,133,333 (+55.67%) | View |